REZOLUTE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.18 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-09-30 was $2.36, a 3.28% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-09-30 was $2.44.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2026 was $2.18, a 23.51% decline from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.85, a 5.63% decline from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.02.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.18 10-K · filed 2026-09-24 | |||
| 2026-03-31 | $2.11 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $2.44 10-Q · filed 2026-02-12 | |||
| 2025-09-30 | $2.36 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $2.85 10-K · filed 2026-09-24 | |||
| 2025-03-31 | $2.80 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $2.85 10-Q · filed 2025-02-12 | |||
| 2024-09-30 | $2.44 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $3.02 10-K · filed 2025-09-17 | |||
| 2024-03-31 | $1.92 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |